Nephrogenic Fibrosing Dermopathy - 15 Studies Found
| Terminated |
: Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) :
|
| Completed |
: Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels :
|
| Completed |
: Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec : Nephrogenic Systemic Fibrosis : 2009-09-21 : Drug: Imatinib mesylate (Glivec) 400 mg, one tablet daily for 12 or 24 weeks |
| Completed |
: Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis : Nephrogenic Systemic Fibrosis : 2009-03-17 |
| Completed |
: Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis : Nephrogenic Systemic Fibrosis : 2008-05-08 : Drug: Imatinib mesylate 400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants dev |
| Suspended |
: Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection :
: 2008-12-18 |
| Suspended |
: Nephrogenic Systemic Fibrosis With Gadollinum :
: 2009-10-26 : Drug: gadollinum use of on injection gadollinum Iv for imaging |
| Completed |
: Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR : Nephrogenic Systemic Fibrosis : 2010-06-01 : Drug: Ablavar One dose of Ablavar will be administered for use during a contrast MRI examination |
| Completed |
: Primovist / Eovist in Renally Impaired Patients : Contrast Media : 2009-05-26 : Drug: Gadoxetic acid disodium (Primovist, BAY86-4873) Primovist/Eovist in approved indications at approv |
| Completed |
: Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist :
: 2008-08-20 : Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882) Patients will be followed for 2 years after the |